Fennec Pharmaceuticals to Announce Q2 2024 Financial Results on August 13, 2024

Fennec Pharmaceuticals Inc., a company dedicated to the development of specialized pharmaceutical products, has announced plans to unveil its second-quarter financial outcomes for 2024. The announcement will precede the commencement of the U.S. financial markets on August 13, 2024. On the same day, the company's management team will host a conference call and webcast to delve into the financial and operational results.

The conference call is scheduled for 8:30 a.m. Eastern Time on August 13, 2024. Interested parties can register for the call via the provided link to obtain a dial-in number and a unique PIN. For those who prefer to join via webcast, the event will be accessible through the company's website under the News & Events section. Participants are encouraged to log in at least 15 minutes early to accommodate any necessary software downloads. Additionally, a replay of the webcast will be available on the Fennec Pharmaceuticals website for 30 days post-event.

In conjunction with the financial results announcement, Fennec Pharmaceuticals will also participate in the 2024 Wedbush PacGrow Healthcare Conference. This event is slated for August 13-14, 2024, in New York, NY. The conference will provide Fennec an opportunity to engage with industry professionals and investors, further solidifying its presence in the healthcare sector.

Fennec Pharmaceuticals is known for its flagship products, PEDMARK® and Pedmarqsi, designed to mitigate the risk of ototoxicity in pediatric patients undergoing platinum-based chemotherapy. PEDMARK received U.S. FDA approval in September 2022, and Pedmarqsi was granted Marketing Authorization by the European Commission in June 2023. The approval of PEDMARK in the U.S. comes with Orphan Drug Exclusivity, granting it seven years of market protection. Similarly, Pedmarqsi in Europe benefits from Pediatric Use Marketing Authorization, ensuring eight years plus an additional two years of data and market protection.

The company has entered into an exclusive worldwide licensing agreement with Oregon Health and Science University (OHSU). This agreement covers intellectual property related to sodium thiosulfate and its application in reducing the risk of ototoxicity due to platinum chemotherapy in humans. This strategic partnership underscores Fennec’s commitment to advancing treatments that address significant unmet medical needs in pediatric oncology.

Fennec Pharmaceuticals remains at the forefront of developing and commercializing therapies that offer critical benefits to pediatric cancer patients. The upcoming financial results release and participation in the Wedbush PacGrow Healthcare Conference highlight the company's ongoing efforts to maintain transparency with its stakeholders and expand its influence within the pharmaceutical industry.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!